The objectives of this study were to investigate the clinical impact of partial volume effects (PVE) correction on the predictive and prognostic value of metabolically active tumor volume (MATV) measurements on 18F-FDG PET baseline scan for therapy response and overall survival in esophageal cancer patients.
With a worldwide estimated 5-year survival of only 15% (1), esophageal cancer is the third most common malignancy of the digestive tract and is a leading cause of cancer mortality. Its incidence is still increasing and there is a growing concern regarding its effective management (2) . Surgical resection remains the most effective treatment, however many patients have a locally advanced esophageal carcinoma (LAEC) at diagnosis and neoadjuvant therapy before surgery has demonstrated improved survival in this case (3) . The maximum improvement in terms of increased overall survival from neoadjuvant treatment is observed for patients who achieve a complete pathological response (only 15-30% of cases) with no residual cancer cells in the primary tumor or lymph nodes (4) . On the other hand, non responders may be unnecessarily affected by toxicity (5) . The development of an early diagnostic test offering non invasive prediction of the response to therapy and/or survival is therefore of great interest. For tumors that cannot be surgically removed, combined radiochemotherapy is the preferred treatment. In this case too, early assessment of response to therapy would allow a modification in the management of non responding patients early during treatment. Such a response assessment becomes even more critical when one considers the availability of new targeted drugs that could be tested with higher efficiency if applied early (6) .
Along with Standardized Uptake Values (SUV, max or peak) usually considered in clinical practice, other parameters describing functional lesions, such as metabolically active tumor volume (MATV, defined as the tumor volume that can be seen and delineated on an 18 F-FDG PET image) (7) , mean SUV and total lesion glycolysis (TLG, defined as the product of MATV and its associated SUV mean ) (8) have been investigated. The prognostic value of these parameters in esophageal cancer patients for overall or disease-free survival has been demonstrated (9) (10) (11) (12) . On the inserm-00707272, version 1 -12 Jun 2012 other hand regarding therapy prediction, several studies on different cancer models have recently suggested using the baseline scan only, instead of the comparison of pre-treatment and post-treatment scans (late assessment) or during-treatment scans (early assessment) (13) . Such investigations were for instance carried out in pleural mesothelioma (14) , non-Hodgkin lymphoma (15) and esophageal cancer (7, 16) , demonstrating higher statistical value for MATV-based parameters than SUV measurements whose predictive value has been found to be conflicting (17) .
However, in most of these studies no partial volume effects (PVE) correction (PVC) was applied which may explain the observed limited value of SUV. The impact of PVC on the clinical value of SUV measurements has been investigated by a limited number of authors. Hoetjes et al (18) investigated the impact of four PVC strategies on 15 breast cancer patients, regarding the early metabolic PET response after one cycle of chemotherapy. The SUV decrease between the pre-treatment scan and the scan early during treatment was found to be lower after PVC (26-27% vs. 31%) for the first three methods but not for the fourth one based on binary tumor masks (30%).
Van Heijl et al (19) recently demonstrated a non-significant impact of PVC on the correlation between disease-free survival and 18 F-FDG PET SUV measurements in 52 esophageal cancer patients. In this study a PVC method based on binary tumor masks generated using adaptive thresholding delineation was used, while diseasefree survival was the only clinical endpoint investigated. Both the use of adaptive thresholding and the PVC method based on tumor masks assume a homogeneous tracer distribution in both tumor and background and are therefore likely to provide only approximate correction (20) . On the other hand, no data is currently available regarding the impact of PVC on the value of baseline measurements for the prediction of overall survival and response to therapy in esophageal cancer.
The current study was therefore carried out to investigate the impact of an advanced PVC methodology and the use of an accurate MATV delineation approach on both the predictive and prognostic value of baseline 18 F-FDG PET scan derived parameters.
MATERIAL AND METHODS

Patients
50 consecutive patients with a newly diagnosed esophageal cancer were included and retrospectively analyzed. The characteristics of the patients are given in table 1.
Most of them (45 out of 50) were male, aged 65±9 years at the time of diagnosis. 74% of the tumors originated from the middle and lower esophagus and 72% were squamous cell carcinoma. None of the patients underwent surgery, and all were treated with concomitant radio-chemotherapy between 2004 and 2009. The therapy regime included three courses of 5-fluorouracil/cisplatin and a median radiation dose of 60Gy given in 180cGy daily fractions delivered once daily, 5 days a week for 6-7 weeks. As part of the routine procedure for the initial staging in esophageal cancer, each patient was referred for an 18 F-FDG PET study before treatment, and these baseline scans were used in this study.
Overall survival was determined as the time between initial diagnosis and last followup or death. Response to therapy was evaluated one month after the completion of the concomitant radio-chemotherapy using conventional thoraco abdominal CT and endoscopy. Patients were classified as non responders (NR, including stable and progressive disease), partial responders (PR) or complete responders (CR).
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Response evaluation was based on CT evolution between pre-treatment and posttreatment scans using RECIST (Response Evaluation Criteria in Solid Tumors) (21) .
Patients also underwent fibroscopy in case of partial or complete response. Complete response was confirmed by the absence of visible disease in the endoscopy and no viable tumor on biopsy. Partial CT response was confirmed by macroscopic residual (>10% viable) on biopsy. No discordance was observed between pathological, when available, and CT evaluation. The current analysis was carried out after an approval by the institutional ethics review board. 
PET image partial volume correction and image analysis
Images were corrected for PVE using an iterative deconvolution methodology that has been previously validated (22) . Its principle is to iteratively estimate the inversion of the scanner's Point Spread Function (PSF), which is assumed to be known and 
Tumor delineation and parameters extraction
For each patient, the tumor was identified on the baseline pretreatment PET images by an experienced nuclear physician. It was then delineated using the Fuzzy Locally
Adaptive Bayesian (FLAB) algorithm (20, 24) on both the original (without PVE correction) and PVE corrected images. This segmentation approach has been shown to give both robust and reproducible functional volume delineations under variable image noise characteristics (25) (26) .
The following parameters were subsequently extracted from each baseline image with or without correction for PVE: SUV max , SUV peak defined as the mean of SUV max and its 26 neighbors (roughly corresponding to a 1cm ROI), mean SUV (SUV mean ) within the volume, MATV, and TLG (determined by multiplying SUV mean with the corresponding MATV).
Statistical analysis
Pearson coefficients were used to estimate correlation between the image derived parameters, and paired t-tests were used to characterize the differences between uncorrected and corrected parameters. The correlation between response to therapy and each parameter was investigated using the Kruskal-Wallis test as a non- (27) . Regarding survival, for each considered parameter, Kaplan-Meier survival curves were generated (28) for which the most discriminating threshold value allowing differentiation of the groups of patients was identified using receiver operating characteristic (ROC) methodology (29) . Prognostic value of each parameter in terms of overall survival was assessed by the log-rank test.
The significance of the following factors (with or without correction) was tested:
SUV max , SUV peak , MATV, SUV mean , and TLG. All tests were performed two-sided using the Medcalc TM statistical software (MedCalc Software, Belgium) and p values below 0.05 were considered statistically significant.
RESULTS
Impact of PVC on the image derived parameters
The PVE correction had an impact on the images that can be assessed visually, with a higher contrast between the tumor and the surrounding tissues, as it can be seen in figure 1 and illustrated using profiles in figure 2. 
Impact of PVC on the predictive and prognostic values
25 patients were classified as PR, 11 were CR and 14 were NR (including stable and progressive disease). With a median follow-up of 60 months (range 10-84), the median overall survival was 12 months and the 1-year and 2-year survival rates were 60% and 35% respectively. 10 patients were alive with no evidence of disease at the time of last follow-up, while 9 were alive with recurrent disease and 31 had died.
Survival was significantly correlated with response, as overall survival was 24±15
(median 21), 22±20 (median 14) and 9±4 (median 10) months for CR, PR and NR figure 5A -B).
Contrary to SUV measurements with or without PVC, the parameters related to functional volume (MATV and TLG) allowed significant (p<0.0001) differentiation of the three response groups, and were significant prognostic factors (p<0.002), as inserm-00707272, version 1 -12 Jun 2012 illustrated in figure 4C . No significant differences were found using the original or PVC corrected values.
The parameter that allowed for the best differentiation of patients groups was the TLG (p<0.0001). CR were characterized by a TLG of 55±45g, whereas PR and NR had a TLG of 178±143g and 416±238g respectively. After PVC, the absolute values of each group rose to 62±45g, 200±155g and 437±249g for CR, PR and NR respectively, leading to the same discrimination between groups of response (p<0.0001). Although slightly less efficient than TLG, the use of MATV allowed a statistically significant differentiation of the three response groups (p<0.0001). Using the MATV values extracted from PVC images led to exactly the same discriminating power (p<0.0001).
MATV and TLG were also good prognostic factors, with high MATV and TLG values being significantly associated with shorter survival with hazard ratios between 3 and 4 (table III). A MATV above 85cm 3 was identified as a predictor of poor outcome with a median survival of 6 months only vs. 20 months for patients with smaller MATV (p=0.0004) as illustrated in figure 5C . In addition, a MATV below 15cm 3 was associated (p=0.009) with longer survival (49 months) than larger MATV (11 months).
Similar results were obtained using the MATVs measured on the PVC corrected images, with a median survival of 20 months for patients with TV PVC below 80cm 3 vs.
10 months (p<0.002). Regarding TLG, a threshold of 260g was found to be a good discriminating factor for outcome (21 vs. 10 months, p=0.0012) whereas using PVC corrected TLG led to similar results with a slightly higher threshold (TLG   PVC   =280g, 21 vs. 10 months, p=0.0004).
inserm-00707272, version 1 -12 Jun 2012
DISCUSSION
Our study investigated the impact of partial volume effects correction on the predictive and prognostic value of different parameters derived using the baseline pre-treatment PET images. Our results confirmed that PVE correction has a significant impact on quantitative SUV values with an average increase of above 50%
for SUV max , in agreement with previous studies (18) (19) , and lower increase (below 30%) for SUV peak and SUV mean . The lower increase observed for SUV peak and SUV mean is related to the fact that the L-R deconvolution is a voxel-by-voxel process As previously demonstrated (7, 12) , MATV and TLG extracted from non corrected As previously demonstrated (7, 12) , MATV and associated TLG values were good predictors of response (7) and independent prognostic factors of overall survival (12) .
After PVC the already high clinical value of MATV and TLG was not significantly altered. Considering the thresholds used to differentiate patient groups, there was no inserm-00707272, version 1 -12 Jun 2012 Hazard ratio 3.9 p = 0.0004 C Figure 5 inserm-00707272, version 1 -12 Jun 2012
